15,601 Shares of Globus Medical, Inc. $GMED Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new stake in Globus Medical, Inc. (NYSE:GMED) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 15,601 shares of the medical device company’s stock, valued at approximately $1,169,000.

Several other hedge funds have also modified their holdings of GMED. Washington Trust Advisors Inc. grew its position in Globus Medical by 116.8% in the second quarter. Washington Trust Advisors Inc. now owns 45,006 shares of the medical device company’s stock valued at $3,556,000 after acquiring an additional 24,250 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Globus Medical during the second quarter valued at approximately $1,858,000. Public Employees Retirement System of Ohio acquired a new position in shares of Globus Medical during the second quarter worth $7,941,000. WCM Investment Management LLC acquired a new position in shares of Globus Medical during the first quarter worth $16,965,000. Finally, Congress Asset Management Co. lifted its position in shares of Globus Medical by 6.6% during the third quarter. Congress Asset Management Co. now owns 361,026 shares of the medical device company’s stock worth $27,041,000 after purchasing an additional 22,401 shares in the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Wells Fargo & Company upped their target price on shares of Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a research note on Friday. Canaccord Genuity Group dropped their price target on shares of Globus Medical from $115.00 to $105.00 and set a “buy” rating on the stock in a research note on Friday. BMO Capital Markets lowered shares of Globus Medical from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $94.00 to $78.00 in a report on Friday. Wall Street Zen cut shares of Globus Medical from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Needham & Company LLC decreased their price objective on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Globus Medical currently has a consensus rating of “Moderate Buy” and an average price target of $96.92.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, ahead of the $1.20 consensus and up from $1.18 a year earlier. Globus also increased its share-repurchase authorization by $500 million, offering potential support for shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Analyst views were mixed: Canaccord and Needham cut their price targets but maintained Buy ratings, while Wells Fargo slightly raised its target and kept an Overweight rating. The company is also seeking acquisitions, though the provided report does not detail potential deals. Report on acquisition plans
• Negative Sentiment: Revenue of $763.7 million missed the $792.4 million analyst estimate and declined 0.7% year over year. Full-year 2026 revenue guidance of $3.1 billion is below the roughly $3.2 billion consensus; management cited spine-product launch delays and weak Nevro sales, weighing on expectations despite EPS guidance being broadly in line. Q3 call highlights and outlook
• Negative Sentiment: BMO Capital Markets downgraded GMED from Outperform to Market Perform and cut its price target, adding to concerns about the outlook. Coverage of the stock decline

Globus Medical Stock Down 0.5%

GMED stock opened at $70.67 on Monday. Globus Medical, Inc. has a 52-week low of $70.39 and a 52-week high of $101.40. The stock’s 50 day moving average is $77.20 and its two-hundred day moving average is $83.18. The company has a market capitalization of $9.49 billion, a PE ratio of 17.36, a P/E/G ratio of 1.14 and a beta of 0.98.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $763.72 million for the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a return on equity of 14.43% and a net margin of 17.76%. Globus Medical’s quarterly revenue was down .7% on a year-over-year basis. During the same period in the prior year, the company posted $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. As a group, sell-side analysts anticipate that Globus Medical, Inc. will post 4.99 EPS for the current year.

Insiders Place Their Bets

In other news, Director Stephen T. Zarrilli sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the completion of the transaction, the director directly owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ann D. Rhoads sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total value of $425,000.00. Following the sale, the director owned 35,384 shares in the company, valued at $3,007,640. The trade was a 12.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 60,000 shares of company stock valued at $4,838,400. Company insiders own 18.38% of the company’s stock.

Globus Medical Company Profile